Matthew C. Hiemenz

Matthew C. Hiemenz

Auto-generated profile, based on publicly available information

Matthew C. Hiemenz

Foundation Medicine, Inc., Cambridge, MA, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Cancer Genetics
Verified
Journal Article
Closed access
MHMatthew C. Hiemenz
Matthew C. Hiemenz
MOMatthew Oberley
Matthew Oberley
ADAndrew Doan
Andrew Doan
LALe Aye
Le Aye
JJJianling Ji
Jianling Ji
GRGordana Raca
Gordana Raca

20 May 2019 in Histopathology
Verified
Journal Article
Closed access
PDF file
MWMikako Warren
Mikako Warren
DADean Anselmo
Dean Anselmo
MTMoe Takeda
Moe Takeda
NSNick Shillingford
Nick Shillingford
MHMatthew C. Hiemenz
Matthew C. Hiemenz
RSRachana Shah
Rachana Shah

11 September 2024 in The Journal of Molecular Diagnostics
Verified
Journal Article
Open access
HAHans-Peter Adams
Hans-Peter Adams
MHMatthew C. Hiemenz
Matthew C. Hiemenz
KHKay Hertel
Kay Hertel
FFFrederike Fuhlbrück
Frederike Fuhlbrück
MTMara Thomas
Mara Thomas
TWThomas Wieland
Thomas Wieland
Increased adoption of personalized medicine has brought comprehensive genomic profiling (CGP) to the forefront. However, differences in assay, bioinformatics, and reporting systems and lack of understanding of their complex interplay are a challenge for implementation and achieving uniformity in CGP testing. Two commercially available, tissue-based, in-house CGP assays were compared, in combination with a tertiary analysis solution in a research use only (RUO) context: the AVENIO Tumor Tissue CGP RUO Kit paired with navify Mutation Profiler (RUO) software and the TruSight Oncology 500 RUO assay paired with PierianDx Clinical Genomics Workspace software. Agreements and differences between the assays were assessed for short variants (SVs), copy number alterations (CNAs), rearrangements, tumor mutational burden (TMB), and microsatellite instability (MSI), including variant categorization and clinical trial-matching (CTM) recommendations. Results showed good overall agreement for SV, known gene fusion, and MSI detection. Important differences were obtained in TMB scoring, CNA detection, and CTM. Differences in variant and biomarker detection could be explained by bioinformatic approaches to variant calling, filtering, tiering, and normalization; differences in CTM, by underlying reported variants and conceptual differences in system parameters. Thus, distinctions between different approaches may lead to inconsistent results. Complexities in calling, filtering, and interpreting variants illustrate key considerations for implementation of any high-quality CGP in the laboratory and bringing uniformity to genomic insight results.

10 April 2024 in The Oncologist
Verified
Journal Article
Open access
JNJoel W Neal
Joel W Neal
KMKatherine Minichiello
Katherine Minichiello
RBRyan Brennick
Ryan Brennick
RHRichard Sheng Poe Huang
Richard Sheng Poe Huang
MHMatthew C Hiemenz
Matthew C Hiemenz
DKDavid Kozono
David Kozono
For cancer clinical trials that require central confirmation of tumor genomic profiling, exhaustion of tissue from standard-of-care testing may prevent enrollment. For Lung-MAP, a master protocol that requires results from a defined centralized clinical trial assay to assign patients to a therapeutic substudy, we developed a process to repurpose existing commercial vendor raw genomic data for eligibility: genomic data reanalysis (GDR). Molecular results for substudy assignment were successfully generated for 369 of the first 374 patients (98.7%) using GDR for Lung-MAP, with a median time from request to result of 9 days. During the same period, 691 of 791 (87.4%) tissue samples received successfully yielded results, in a median of 14 days beyond sample acquisition. GDR is a scalable bioinformatic pipeline that expedites reanalysis of existing data for clinical trials in which validated integral biomarker testing is required for participation.